Lipid drug conjugate (LDC) nanoparticles as autolymphotrophs for oral delivery of methotrexate.
The objective of the study was to develop lipid drug conjugate nanoparticles (LDC-NPs) of anticancer drug methotrexate (MTX) for oral delivery that faces problems of low and variable bioavailability. The MTX loaded LDC-NPs significantly enhanced bioavailability and reduced MTX associated gastrointestinal toxicity even in higher doses recommended for anticancer therapy.